Reflux Nephropathy Treatment Market - Global Industry Trend Analysis 2012 to 2017 and Forecast 2017 - 2025


Persistence Market Research

$ 4900

Reflux Nephropathy is the condition of kidney damage due to the backward flow of urine from bladder into kidneys. The disease is more common in children and causes inveterate childhood abnormality in urinary tract and the long term disease is alleged to cause chronic pyelonephritis, high blood pressure, excessive protein loss, obstructive uropathy and kidney failure. Reflux Nephropathy is supposed to occur in people whose ureters are not attached properly to the bladder, when the valves are not working well or at the time of kidney transplant followed by the swelling of ureters. The treatment of Reflux Nephropathy includes surveillance, medical therapy and surgical therapy which is distributed among 5 different grades depending upon the gravity of reflux.  The treatment of reflux nephropathy aims to reduce the renal scarring and kidney infections by usage of Prophylactic Antibiotics, antihypertensive medications, pain medications, urine culture and yearly ultrasound of the kidneys. The severe reflux nephropathy require surgery when the medical therapy fails to respond. In few cases, surgery includes ureteral re-implantation to stop the backward flow of urine. The treatment of the reflux nephropathy depends on the gender and age of the patient. The medical therapy is the safest treatment among all the diagnostic treatments as the surgical approach may face some unavoidable complications.

Reflux Nephropathy is a congenital disease which causes an increase in the number of people suffering from the disease. Advancement in medication and surgical therapies, follow up care and imaging techniques impact the overall treatment market.

Reflux Nephropathy Treatment Market: Drivers & Restraints

The emerging research and development by various academic and research institutes as well as bio-pharmaceutical companies contributes to the opening of novel treatment approaches participating in increasing the overall global market. Several awareness programs organized by government and health care sector has also led to an upsurge in the market. The drugs like antibacterial pyelonephritis and antibody trimethoprim-sulfamethoxazole are effective antibiotic to prevent the infections but the scarcity of the drugs and threat to the patients in the surgical treatment of reflux nephropathy turns to be the limiting factor for the growth of market.

Reflux Nephropathy Treatment Market: Segmentation

By Treatment Type:

  • Prophylactic Antibiotics
  • Antihypertensive medications
  • Pain Medications
  • Others

By Distribution Channels:

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies

Continuous research in the area and novel product launches would provide edge to the bio pharmaceutical companies involved in the competition landscape. The research and development in the diagnostic methodology has also accelerated the progress of market. The medical therapy is the most preferred treatment method that contributes to a major part of the total market of reflux nephropathy treatment. Availability of generic medications in the market also have an impact in the overall growth of Nephropathy treatment market.

Geographically, the reflux nephropathy treatment market has been segmented into five key regions: North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America dominates the market because of the availability of large number of service providers and good reimbursement scenario for the treatment. This is followed by the Europe as studies demonstrates, children in these regions are 10 times more susceptible to the disease. Moreover, the health facilities and healthy reimbursement scenario is also at pinnacle in these regions. The market in Asia Pacific and Middle Eastern countries is considered to be the growing segments due to the continuous increasing number of service providers and improvement in healthcare facilities. The awareness programs conducted by the health organizations also assists the overall growth of the market in these regions.

Some major key players of the reflux nephropathy treatment market are Abbott India Ltd., Glaxo SmithKline Pharmaceutical Ltd, Cubit Healthcare, Cobalt Laboratories Inc, Actavis Mid Atlantic LLC, Aurobindo Pharma - Milpharm Ltd.

MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

The report provides the following information:

  • Tailwinds and headwinds molding the market’s trajectory
  • Market segments based on products, technology, and applications
  • Prospects of each segment
  • Overall current and possible future size of the market
  • Growth pace of the market
  • Competitive landscape and key players’ strategies

The main aim of the report is to:

  • Enable key stakeholder’s in the market bet right on it
  • Understand the opportunities and pitfalls awaiting them
  • Assess the overall growth scope in the near term
  • Strategize effectively with respect to production and distribution

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.